Income Statement (TTM)
Summit Therapeutics Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 |
| Change (%) | 24.54 | -15.35 | -15.52 | 183.41 | 3.79 | 3.21 | 9.53 | -53.25 | -26.26 | -35.46 | -51.65 | -100.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cost Of Sales | |||||||||||||
| Change (%) | |||||||||||||
| % of Revenue | |||||||||||||
| Gross Operating Profit | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 |
| Change (%) | 24.54 | -15.35 | -15.52 | 183.41 | 3.79 | 3.21 | 9.53 | -53.25 | -26.26 | -35.46 | -51.65 | -100.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| SG&A | 21 | 19 | 20 | 20 | 19 | 24 | 26 | 27 | 27 | 27 | 27 | 26 | 26 |
| Change (%) | -6.55 | 3.19 | 1.06 | -5.90 | 25.12 | 10.48 | 3.64 | -0.33 | -0.75 | 1.05 | -2.28 | -0.53 | |
| % of Revenue | 2,980.16 | 2,236.28 | 2,725.96 | 3,260.98 | 1,082.67 | 1,305.20 | 1,397.16 | 1,321.96 | 2,818.51 | 3,793.33 | 5,939.34 | 12,003.18 | |
| R&D | 51 | 53 | 59 | 69 | 75 | 85 | 88 | 73 | 70 | 52 | 43 | 43 | 41 |
| Change (%) | 4.35 | 10.26 | 17.62 | 9.00 | 13.34 | 2.55 | -17.04 | -3.99 | -25.42 | -18.09 | 1.04 | -4.01 | |
| % of Revenue | 7,393.00 | 6,194.65 | 8,068.82 | 11,234.47 | 4,320.65 | 4,718.19 | 4,688.22 | 3,550.81 | 7,292.89 | 7,375.74 | 9,360.66 | 19,560.91 | |
| OpEx | 52 | 53 | 61 | 69 | 73 | 88 | 93 | 82 | 79 | 64 | 59 | 62 | 66 |
| Change (%) | 3.06 | 14.01 | 13.62 | 6.58 | 19.82 | 6.02 | -11.64 | -4.41 | -18.36 | -7.62 | 4.82 | 5.35 | |
| % of Revenue | 7,474.11 | 6,185.35 | 8,330.36 | 11,204.23 | 4,213.31 | 4,864.29 | 4,996.68 | 4,030.71 | 8,241.95 | 9,124.26 | 13,059.78 | 28,313.18 | |
| Operating Income | -51 | -52 | -60 | -68 | -72 | -86 | -91 | -80 | -78 | -64 | -59 | -62 | -66 |
| Change (%) | 2.77 | 14.49 | 13.98 | 4.98 | 20.21 | 6.07 | -12.07 | -3.17 | -18.26 | -7.32 | 5.26 | 5.72 | |
| % of Revenue | -7,374.11 | -6,085.35 | -8,230.36 | -11,104.23 | -4,113.31 | -4,764.29 | -4,896.68 | -3,930.71 | -8,141.95 | -9,024.26 | -12,959.78 | -28,213.18 | |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -4 | -13 | -14 | -16 |
| Change (%) | -19.67 | -0.00 | 94.90 | 0.40 | -51.50 | 62.81 | 104.31 | 85.71 | 194.38 | 185.75 | 14.81 | 14.06 | |
| % of Revenue | -45.97 | -29.65 | -35.03 | -80.81 | -28.63 | -13.38 | -21.10 | -39.36 | -156.38 | -624.26 | -2,763.96 | -6,562.73 | |
| Net Income | -51 | -53 | -64 | -73 | -75 | -89 | -93 | -85 | -87 | -79 | -600 | -598 | -598 |
| Change (%) | 3.56 | 21.55 | 14.27 | 2.54 | 18.07 | 4.41 | -8.26 | 2.10 | -9.08 | 661.29 | -0.34 | -0.02 | |
| % of Revenue | -7,368.95 | -6,127.56 | -8,798.21 | -11,900.49 | -4,305.45 | -4,897.84 | -4,955.06 | -4,149.93 | -9,064.02 | -11,174.75 | -131,815.60 | -271,685.00 | |
Source: Capital IQ
